Clinical Trial Update: A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) [Phase 1]

View source ↗

Summary

A Phase 1b study of SMT C1100 in Duchenne Muscular Dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SMT C1100 (SMT C1100)

Snippet

Sponsor: Summit Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 1 | Status: COMPLETED